Monitor upcoming earnings reports for initial sales traction and surgeon adoption rates of the InSet I-135RFX. Given the strong analyst sentiment (92% bullish) and the strategic expansion of SI's product portfolio, this launch could drive near-term upside if early commercial performance meets expectations.
Price Chart
Executive Summary
Shoulder Innovations, Inc. (SI) announced the full commercial launch of its InSet I-135RFX Humeral Stem, a new shoulder implant device that expands its product line to cover all primary, revision, and fracture total shoulder arthroplasty procedures. The launch follows FDA 510(k) clearance and a successful limited market release, enhancing the company's competitive positioning in the surgical implant market.
Key Facts
- Full commercial launch of the InSet I-135RFX Humeral Stem announced.
- Product enables use in all primary, revision, and fracture total shoulder arthroplasty procedures.
- Follows successful limited market release and additional FDA 510(k) clearance.
- Third addition to the I-Series humeral stem product line in three years.
- Device integrates with existing two-tray surgical instrumentation system and is valued for ease of use.
Financial Impact
Potential revenue growth from expanded product offering; no specific financial figures disclosed.
Risk Factors
- No immediate financial impact data provided; revenue contribution will depend on market adoption.
- Competitive response from larger orthopedic device manufacturers could limit market penetration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001699350-26-000021 |
| Exhibit: ex-991pressrelease4x27x2026.htm | 0001699350-26-000021 |
| Document: 0001699350-26-000021-index-headers.html | 0001699350-26-000021 |
| Document: 0001699350-26-000021-index.html | 0001699350-26-000021 |
| Document: 0001699350-26-000021.txt | 0001699350-26-000021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 11d ago | Press Release | $18.09 | awaiting T+60 | — | $19.66 (+8.68%) |
Oct 8, 2026 18d ago | 8-K | $17.89 | awaiting T+60 | — | $19.66 (+9.89%) |
Aug 24, 2026 9w ago | Insider Cluster | $22.32 | awaiting T+60 | — | $19.66 (−11.92%) |
Aug 14, 2026 10w ago | EFFECT | $20.73 | awaiting T+60 | — | $19.66 (−5.16%) |
Aug 10, 2026 11w ago | 8-K | $20.75 | awaiting T+60 | — | $19.66 (−5.25%) |
Jul 29, 2026 12w ago | 144 | $23.72 $19.75 | ▲ +16.74% | ▲ +21.47% | $19.66 (+17.12%) |
Jun 29, 2026 17w ago | 8-K | $21.09 $17.61 | ▼ −16.50% | ▼ −20.89% | $19.66 (−6.78%) |
May 13, 2026 23w ago | 8-K | $15.59 $20.75 | ▲ +33.10% | ▲ +29.51% | $19.66 (+26.11%) |
Apr 29, 2026 25w ago | DEFA14A | $12.28 $20.41 | ▲ +66.21% | ▲ +62.09% | $19.66 (+60.10%) |
Apr 27, 2026 26w ago | 8-K | $13.53 $20.31 | ▲ +50.11% | ▲ +45.33% | $19.66 (+45.31%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers